TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22674146
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) - epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 100 mg/m(2) for 4 cycles (EC-T)
Study: 22674146
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) - exemestane 25 mg daily for 24 weeks (combined with goserelin in premenopausal patients)
Study: 11844818
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus weekly CDDP chemotherapy (40 mg/m(2))
Study: 11844818
Drug: RT without
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT without chemotherapy
Study: 10076721
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by adjusted locoregional treatment
Study: 10076721
Drug: Initial mastectomy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial mastectomy followed by adjuvant chemotherapy
Study: 7672547
Drug: Nd: YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd: YAG laser therapy
Study: 7672547
Drug: Injection-assisted piecemeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection-assisted piecemeal polypectomy
Study: 27996339
Drug: Bowen systemic
Normalized name: potassium sulfate
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Bowen systemic family therapy (eight 90‐minute sessions)
Study: 23200124
Drug: Preoperative carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative carbohydrate treatment (PCT) ≥50 g oral carbohydrates 2-4 h pre-anaesthesia
Study: 23200124
Drug: Preoperative carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative carbohydrate treatment (PCT)
Study: 19419595
Drug: Ziprasidone (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (80-160 mg/d)
Study: 18716688
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg tobramycin twice‐daily continuous treatment
Study: 18716688
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tobramycin twice daily in cycles of 28 days on and 28 days off treatment
Study: 17152857
Drug: Midodrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (5 mg orally) given to female subjects 1 hour before post-TST
Study: 8287567
Drug: Biosynthetic GH
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic GH replacement therapy (0.25 IU/kg/week)
Study: 2882294
Drug: 1 microgram,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram, 30 micrograms, or 1000 micrograms doses of recombinant gamma interferon (IFN‐gamma), given by intravenous infusion twice a week for four weeks
Study: 2882294
Drug: 1 microgram,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram, 30 micrograms, or 1000 micrograms doses of recombinant gamma interferon (IFN‐gamma)
Study: 31385885
Drug: Pinaverium Bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium Bromide 100 mg plus Simethicone 300 mg (PB+S)
Study: 30141237
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (2 mg/day) of aripiprazole adjunctive to antidepressant therapy
Study: 26316698
Drug: Biphasic immediate-release/extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic immediate-release/extended-release oxycodone/acetaminophen 7.5/325mg tablets (one tablet), 15/650mg (two tablets), or 30/1,300mg (four tablets) under fasted conditions
Study: 26316698
Drug: Biphasic immediate-release/extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic immediate-release/extended-release oxycodone/acetaminophen 7.5/325mg tablets under fed conditions
Study: 24079037
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.9% sodium chloride solution in WLL)
Study: 20076856
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 microg/kg)
Study: 16387583
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (100 mug twice daily)
Study: 16387583
Drug: Montelukast (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5-10 mg nightly, age dependent)
Study: 15057400
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam (Group B)
Study: 15057400
Drug: No pre‐medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre‐medication (Group A)
Study: 3882899
Drug: Pentobarbital treatment
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentobarbital treatment (27 cases)
Study: 22053074
Drug: Transdermal GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal GTN (0.6 mg/h)
Study: 22053074
Drug: Co-infusion of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-infusion of antioxidant vitamin C with rosiglitazone and GTN
Study: 20473738
Drug: Tanreqing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanreqing Injection (TRQI)
Study: 20473738
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group A (15 mg ambroxol hydrochloride twice a day)
Study: 20473738
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group B (conventional Western medicine treatment only)
Study: 18269068
Drug: Treatment strategies
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment strategies for patients with acute decompensated heart failure and poor renal function
Study: 12501880
Drug: Once-weekly alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly alendronate 70 mg
Study: 12412806
Drug: Twice-weekly alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly alendronate 35 mg
Study: 12412806
Drug: Daily alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily alendronate 10 mg
Study: 10902536
Drug: Test meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test meal (250g curd, 150g yoghurt, 3 slices pineapple, 2 breakfast rolls, 2 cups of coffee, 10g coffee cream, 20g butter, 50g jam, 20g honey; 580mg Ca)
Study: 10902536
Drug: Lactogluconate effervescent
Normalized name: calcium galactogluconate bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactogluconate effervescent tablet (500mg Ca)
Study: 7595245
Drug: Orthographic similarity
Normalized name: Antigonadotropins and similar agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthographic similarity (e.g., keller‐KELLER, cellar‐ladle)
Study: 7595245
Drug: Morphological relatedness
Normalized name: Emergency Preparedness KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphological relatedness (e.g., kellen‐KELLE, ladles‐ladle)
Study: 3711379
Drug: Oral 8‐methoxypsoralen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 8‐methoxypsoralen
Study: 31635021
Drug: BoNT/A treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/A treatment for chronic migraine
Study: 27390050
Drug: Oppanol® PIB‐containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oppanol® PIB‐containing transdermal therapeutic system (TTS) formulation (0.3 mg clonidine/24 h)
Study: 27390050
Drug: All patch
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patch types (T1/R1, R1/T1, T2, R2)
Study: 24509969
Drug: Topical scar
Normalized name: Mederma Advanced Scar Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical scar gel containing extract of Allium cepae, allantoin, and heparin (Contractubex) applied twice daily
Study: 21689142
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg for 10 days
Study: 21689142
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg for 10 days
Study: 18467080
Drug: Adjuvant radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiotherapy plus chemotherapy
Study: 7844217
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (50 mg/day for 5 days) and IUI (clomiphene/IUI group)
Study: 7844217
Drug: Late low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Late low-dose pure follicle stimulating hormone (FSH, 75 IU/day from day cycle 7 until the leading follicle reached > 17 mm in diameter) and IUI (FSH/IUI group)
Study: 3395259
Drug: Controlled-release carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release carbidopa/levodopa 50/200 (SINEMET CR)
Study: 31506853
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) in addition to standard medical care
Study: 26132687
Drug: D-Cycloserine plus
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Cycloserine plus exposure therapy (n = 20)
Study: 26132687
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus exposure therapy (n = 16)
Study: 24133627
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (100 mg/day for 6-10 months)
Study: 21367625
Drug: Acarbose 50
Normalized name: acarbose 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 50 mg three times a day (titrated to 100 mg after one month)
Study: 18326618
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE), 890 mg polyphenols and 366 mg EGCG, taken as 3 capsules before exercise
Study: 12716269
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment (individually tailored remedy)
Study: 10715299
Drug: IV methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV methotrexate (MTX) 1,000 mg/m2 plus IV mercaptopurine (MP) 1,000 mg/m2 (regimen A)
Study: 10715299
Drug: IV methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV methotrexate (MTX) 1,000 mg/m2 alone (regimen C)
Study: 26716365
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messages for adherence for 21 days plus usual care
Study: 23299530
Drug: Cediranib 20
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 20 mg with mFOLFOX6
Study: 23299530
Drug: Cediranib 30
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 30 mg with mFOLFOX6
Study: 23299530
Drug: Cediranib 20
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 20 mg
Study: 19900491
Drug: GLP-2 (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-2 (450 nmol subcutaneous)
Study: 15935648
Drug: Chlorhexidine spray
Normalized name: chlorhexidine Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine spray (0.5% in alcoholic solution)
Study: 15935648
Drug: Chlorhexidine sachet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine sachet (0.05% aqueous solution)
Study: 12930191
Drug: 180 g
Normalized name: GLYCERIN 9 mg in 180 g / PANTHENOL 7 mg in 180 g CUTANEOUS FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 g EGb 761
Study: 1860302
Drug: Ranitidine pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine pretreatment (five 150-mg oral doses given every 12 hours)
Study: 7334938
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 2 mg of micronized oestradiol and 1 mg of micronized oestriol (Estrofem)
Study: 7334938
Drug: Aqueous suspension
Normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous suspension of the same micronized hormones
Study: 26764121
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate (UPA) 30 mg administered every 7 days (Q7D)
Study: 26764121
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate (UPA) 30 mg administered every 5 days (Q5D)
Study: 23809278
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate (UPA) 30 mg
Study: 24796046
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + Zhangmo decoction group (C)
Study: 24796046
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + Zhangmo decoction + warm needling group (D)
Study: 24796046
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + progynova group (B)
Study: 18815997
Drug: 14-week integrated
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-week integrated treatment targeting anger and addictions (i.e., both gambling and substance use)
Study: 18815997
Drug: Specialized treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized treatment-as-usual (TAU) for gambling and substance use
Study: 17189398
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg sorafenib twice daily plus best supportive care
Study: 17189398
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg sorafenib twice daily
Study: 10226868
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 4 or 8 mg once daily
Study: 15700491
Drug: Doxazosin standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin standard 1 mg to 8 mg once daily
Study: 8765624
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (6 mg/kg per week)
Study: 8765624
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous lactate (elemental iron, 12 mg/kg per day)
Study: 28642209
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral naltrexone (50mg)
Study: 26138865
Drug: Empagliflozin 5
Normalized name: empagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 5 mg BID
Study: 26138865
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg QD
Study: 21482091
Drug: 18 μg
Normalized name: ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18 μg of tiotropium bromide plus 200 μg salbutamol
Study: 12919709
Drug: Cyclic therapy
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic therapy with etidronate (400 mg/day for 2 weeks followed by 500 mg/day of calcium lactate for 12 weeks, repeated every 14 weeks)
Study: 3824375
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg twice daily after breakfast and at bedtime
Study: 9041463
Drug: Low-dose IFN,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose IFN, 6 x 10(6) U/m2 daily x 3 every 4 weeks
Study: 9041463
Drug: High-dose IFN,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN, 12 x 10(6) U/m2, 3 x/week
Study: 9041463
Drug: Both low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both low-dose and high-dose IFN
Study: 9041463
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving >= 6 weeks of therapy
Study: 1424422
Drug: Fluoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (40 mg/day)
Study: 6366561
Drug: Nifedipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (60 mg per day)
Study: 6366561
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg per day)
Study: 22573431
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (400 IU/day) and Calcium (1,000 mg elemental)
Study: 20147467
Drug: Vegetable portion
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable portion size increased (180, 270, or 360 g)
Study: 20147467
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in vegetable energy density (0.8 or 0.4 kcal/g)
Study: 20147467
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of substitution and reduction in energy density
Study: 7738889
Drug: Intravenous cholangiography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cholangiography (IVC)
Study: 1917621
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment time within 49 days (≤ 7 weeks)
Study: 1917621
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment time 50 to 63 days (8 to 9 weeks)
Study: 1917621
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment time ≥ 64 days (> 9 weeks)
Study: 25668435
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin administration (24 IU)
Study: 19336851
Drug: 2% amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% amitriptyline gel
Study: 15021286
Drug: 25G needle
Normalized name: NEEDLE 25G 1IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25G needle injection
Study: 2510329
Drug: Enoxacin 400
Normalized name: enoxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 400 mg
Study: 28984772
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: fluid‐air exchange tube connected to a 1 mL syringe with the plunger removed and the tip dilated with a hemostat.
Study: 21168116
Drug: Qigong training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong training for half an hour daily for six weeks
Study: 18997197
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg daily)
Study: 9759611
Drug: GPIIb/IIIa‐inhibitor MK383
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPIIb/IIIa‐inhibitor MK383
Study: 9759611
Drug: Heparin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (0.2 U/ml)
Study: 7886407
Drug: Furosemide with
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide with placebo pre-treatment
Study: 7886407
Drug: Furosemide with
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide with captopril pre-treatment
Study: 7886407
Drug: Furosemide with
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide with prazosin pre-treatment
Study: 3229117
Drug: Small doses
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small doses of heparin (2 X 5000 u. subcutaneously/24 h)
Study: 31984443
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 200 U/ml (degludec U200)
Study: 31984443
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/ml (glargine U300)
Study: 30497483
Drug: Chuna manual
Normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chuna manual therapy (10 sessions, twice a week for 5 weeks)
Study: 30497483
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (conventional physical therapy and medication treatment)
Study: 30497483
Drug: Chuna manual
Normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chuna manual therapy
Study: 25155416
Drug: Acid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acid infusion into the distal esophagus
Study: 25953832
Drug: Intranasal scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal scopolamine (0.4 mg)
Study: 26268532
Drug: Intranasal scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal scopolamine
Study: 18296328
Drug: 50mg L-theanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg L-theanine
Study: 15642700
Drug: Nebivolol (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (titrated from 1.25 mg once daily to 10 mg once daily, mean maintenance dose 7.7 mg)
Study: 15642700
Drug: Placebo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mean maintenance dose 8.5 mg)
Study: 10666558
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of haloperidol
Study: 29170792
Drug: 5% prilocaine/lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% prilocaine/lidocaine (EMLA) cream
Study: 29170792
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin suppository
Study: 25680360
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only users
Study: 25680360
Drug: Participants not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants not utilizing medications or psychotherapy